Tumor markers in DCIS breast cancer. Prediction of endocrine treatment and radiotherapy. 2

Tumor markers in DCIS breast cancer. Prediction of endocrine treatment and radiotherapy. 2

Tumor markers in DCIS breast cancer. Prediction of endocrine treatment and radiotherapy. 2

Can we help?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


You are leading clinical trials that identified the specific cancer markers in DCIS, Ductal Carcinoma In Situ. It is a breast cancer. This marker may predict breast cancer recurrence. Cancer marker may predict what treatments may or may not be given. Dr. Anton Titov, MD. What can you tell about that research? Dr. Jack Cuzick, PhD. I think this is a very important area of breast cancer research. Because we do know that not all DCIS progress to invasive breast cancer. The first challenge is to determine whether this DCIS has progressive potential to invasive breast cancer. We have to determine if DCIS patient needs additional treatment. Most of DCIS cases can be treated simply by surgery. Dr. Jack Cuzick, PhD. Radiotherapy maybe *not* even required. The first cancer markers we looked at were important for invasive breast cancer. we looked at estrogen receptor positivity, progesterone receptor positivity, HER2 positivity. We also looked at Ki-67 cancer marker as a measure of tumor proliferation index. Those breast tumor markers are potentially quite useful. But it's still early days of research. We are in the process of doing a large clinical trial based on our first DCIS clinical trial. This is 1,700 breast cancer patients. We have blocks of breast cancer biopsy tissue on over a thousand of patients now. So that work is ongoing. The only work that's been completed has been done for the estrogen receptor and for HER2 receptor in breast cancer. Dr. Jack Cuzick, PhD. There is evidence that HER2 is important for predicting response of breast cancer to radiotherapy. That research result is not published yet. But it has been presented at a scientific medical meeting. Dr. Anton Titov, MD. We do believe that estrogen receptors are very important for determining which breast cancer patient needs endocrine therapy.

More from Breast Cancer
Seek second opinion from a clinical physician or surgeon. Not from a radiologist. 15
$0.00
Breast cancer, obesity, and insulin. How metformin helps to delay cancer. 3
$0.00
Hormone-resistant breast cancer. New endocrine therapy of cancer. 2
$0.00
How to prevent breast cancer? Chemoprevention with aromatase inhibitors. 10
$0.00
Early breast cancer, DCIS. How to decide on best therapy? 3
$0.00
Tumor markers in DCIS breast cancer. Prediction of endocrine treatment and radiotherapy. 2
$0.00
Recently viewed Expert Conversations

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.

Refine your treatment plan to perfection by a panel of 3 to 10+ top doctors that are perfect for you.


Can we help?

Find perfect surgeons or medical specialists to perform your treatment.

Find perfect surgeons or medical specialists to perform your treatment.


How it works
Find perfect surgeons or medical specialists to perform your treatment.